Rivastigmine in the treatment of dementia with Lewy bodies: preliminary findings from an open trial

The objective of this study was to assess the tolerability and efficacy of rivastigmine in a group of patients with probable dementia with Lewy bodies (DLB), using an open label study. Open label treatment was with rivastigmine up to maximum tolerated dose (mean 9.6 mg daily, range 3–12 mg). Eleven patients with DLB, mean age 78.5 years, were treated with this cholinesterase inhibitor. After 12 weeks of treatment, mean Neuropsychiatric Inventory scores fell by 73% for delusions, 63% for apathy, 45% for agitation and 27% for hallucinations. Five of the patients (45%) experienced very significant clinical improvements that had not been achieved with other treatments, including low dose neuroleptics. Medication was well tolerated and parkinsonian symptoms tended to improve. Cholinesterase inhibition may be a safe and effective alternative to neuroleptic treatment in DLB. Such effects may also prove to be applicable to the management of neuropsychiatric symptoms in Parkinson's disease and Alzheimer's disease. Copyright © 2000 John Wiley & Sons, Ltd.

[1]  I. McKeith,et al.  Olanzapine in dementia with Lewy bodies: a clinical study , 1999, International journal of geriatric psychiatry.

[2]  P. Lantos,et al.  Validity of current clinical criteria for Alzheimer's disease, vascular dementia and dementia with Lewy bodies , 1999, British Journal of Psychiatry.

[3]  O. Lopez,et al.  Dementia with Lewy bodies , 1998, Neurology.

[4]  K. Rockwood,et al.  Donepezil for Treatment of Dementia With Lewy Bodies: A Case Series of Nine Patients , 1998, International Psychogeriatrics.

[5]  B. Gulanski,et al.  Metrifonate treatment of the cognitive deficits of Alzheimer's disease , 1998, Neurology.

[6]  M. Beal,et al.  Case 7-1998 , 1998 .

[7]  R. Mohs,et al.  A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease , 1998, Neurology.

[8]  D. Benson,et al.  Dementia with Lewy bodies , 1996, Neurology.

[9]  K. Kosaka,et al.  Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB) , 1996, Neurology.

[10]  M. Hutchinson,et al.  Cholinesterase inhibition in Parkinson's disease. , 1996, Journal of neurology, neurosurgery, and psychiatry.

[11]  J. Pearce.  Longus cervicis colli "myositis" (syn: retropharyngeal tendinitis) , 1996, Journal of neurology, neurosurgery, and psychiatry.

[12]  I. McKeith,et al.  Neuroleptic sensitivity to risperidone in Lewy body dementia , 1995, The Lancet.

[13]  M. Mega,et al.  The Neuropsychiatric Inventory , 1994, Neurology.

[14]  G. Wilcock,et al.  Tacrine for senile dementia of Alzheimer's or Lewy body type , 1994, The Lancet.

[15]  D. Collier,et al.  DRD2 Ser311/Cys311 polymorphism in schizophrenia , 1994, The Lancet.

[16]  Mrinalini Honavar,et al.  Lewy bodies and response to tacrine in Alzheimer's disease , 1994, The Lancet.

[17]  D. G. Gorman,et al.  Physostigmine ameliorates the delusions of Alzheimer's disease , 1993, Biological Psychiatry.

[18]  E. Perry,et al.  Neuroleptic sensitivity in patients with senile dementia of Lewy body type. , 1992, BMJ.

[19]  S. Folstein,et al.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.

[20]  E. Perry,et al.  Dementia with Lewy Bodies: Altered consciousness and transmitter signalling in Lewy body dementia , 1996 .

[21]  S. Fahn.  Unified Parkinson's Disease Rating Scale , 1987 .